UY32235A - Combinacion farmaceutica sinergica que comprende un antagonista del receptor de estrogeno y una progestina - Google Patents

Combinacion farmaceutica sinergica que comprende un antagonista del receptor de estrogeno y una progestina

Info

Publication number
UY32235A
UY32235A UY0001032235A UY32235A UY32235A UY 32235 A UY32235 A UY 32235A UY 0001032235 A UY0001032235 A UY 0001032235A UY 32235 A UY32235 A UY 32235A UY 32235 A UY32235 A UY 32235A
Authority
UY
Uruguay
Prior art keywords
antigonist
progestine
strogen
pharmaceutical
receiver
Prior art date
Application number
UY0001032235A
Other languages
English (en)
Spanish (es)
Inventor
Dr Tim Wintermantel
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY32235A publication Critical patent/UY32235A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
UY0001032235A 2008-11-11 2009-11-10 Combinacion farmaceutica sinergica que comprende un antagonista del receptor de estrogeno y una progestina UY32235A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102008057230A DE102008057230A1 (de) 2008-11-11 2008-11-11 Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin

Publications (1)

Publication Number Publication Date
UY32235A true UY32235A (es) 2010-06-30

Family

ID=41606625

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032235A UY32235A (es) 2008-11-11 2009-11-10 Combinacion farmaceutica sinergica que comprende un antagonista del receptor de estrogeno y una progestina

Country Status (6)

Country Link
AR (1) AR074297A1 (de)
DE (1) DE102008057230A1 (de)
PA (1) PA8847901A1 (de)
TW (1) TW201022251A (de)
UY (1) UY32235A (de)
WO (1) WO2010054758A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102481294A (zh) * 2009-09-11 2012-05-30 拜耳医药股份有限公司 作为抗癌药物的取代(杂芳基甲基)乙内酰硫脲
WO2013131105A1 (en) * 2012-03-02 2013-09-06 Sri International Synergistic anti-proliferation activity of tas-108 with mtor inhibitors against cancer cells
WO2016004166A1 (en) * 2014-07-02 2016-01-07 Xavier University Of Louisiana Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
CN104370796B (zh) * 2014-11-21 2016-09-14 扬子江药业集团有限公司 一种醋酸巴多昔芬多晶型b的制备方法
KR20180059427A (ko) 2015-07-14 2018-06-04 노벨파마 컴퍼니 리미티드 에스트로겐 수용체 α 저해 작용을 갖는 에스트로겐 수용체 β 부분 아고니스트 및 이를 사용한 부인과 질환 치료제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19635525A1 (de) 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
UA68365C2 (en) * 1997-11-06 2004-08-16 Wyeth Corp Peroral contraception by combination of anti-estrogen and progestin
US6265393B1 (en) 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
DE60005693T2 (de) * 1999-07-29 2004-07-29 Eli Lilly And Co., Indianapolis Eine kristalline form von 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophen-hydrochlorid
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE10159217A1 (de) 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
WO2003063859A1 (en) * 2002-01-14 2003-08-07 Nordic Bioscience A/S Suppression of cartilage degradation via the estrogen receptor
TW200307553A (en) * 2002-05-24 2003-12-16 Akzo Nobel Nv Treatment of post-menopausal complaints in breast cancer patients
JP4656939B2 (ja) 2002-07-22 2011-03-23 イーライ リリー アンド カンパニー フェニルスルホニル基を含む選択的エストロゲン受容体モジュレーター
US20080021003A1 (en) * 2006-06-13 2008-01-24 Vladimir Hanes Extended step-down estrogen regimen

Also Published As

Publication number Publication date
TW201022251A (en) 2010-06-16
WO2010054758A1 (en) 2010-05-20
PA8847901A1 (es) 2010-06-28
AR074297A1 (es) 2011-01-05
DE102008057230A1 (de) 2010-05-12

Similar Documents

Publication Publication Date Title
CR20110455A (es) Derivados de indol como antagonistas del receptor crth2
UY32819A (es) Composiciones farmaceuticas de uso oftalmico de antagonistas del receptor dp2
GT201500233A (es) Derivados de benzotiofeno y composiciones de los mismos como degradantes selectivos de los receptores de estrógeno
GT201200147A (es) Antagonistas de espiro-oxindol de mdm2
CR20150296A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
GT201600056A (es) Derivados de quinolizina sustituidos utiles como inhibidores de integrasa del vih
GT201300122A (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
ECSP12012270A (es) Compuestos de pirazol como inhibidores del receptor sigma
CO6480918A2 (es) Antagonistas policíclicos de receptores de ácido lisofosfatídico.
NI201500004A (es) Métodos y composiciones para determinar la resistencia a la terapia con receptor de andrógeno.
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
SV2010003687A (es) Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
HN2012000137A (es) Derivados de 17 - hidroxi - 17 - pentafluoroetil - estra - 4, 9(10) - dien - 11 - arilo, procedimientos para su preparacion y su uso para el tratamiento de enfermedades
UY32235A (es) Combinacion farmaceutica sinergica que comprende un antagonista del receptor de estrogeno y una progestina
CU20120175A7 (es) Compuestos derivados de 6,7-dihidro-5h-benzo[7]anulenos
CO6420342A2 (es) Derivados de pirazol usados como antagonistas del receptor ccr4
BR112015030387A2 (pt) compostos de pirazol como moduladores de fshr e usos dos mesmos
DOP2013000285A (es) El anticuerpo neutralizador del receptor de prolactina mat3 y su uso terapéutico
UY35906A (es) Novedosos derivados de bencimidazol como ligandos de ep4
CL2016002240A1 (es) Derivados de piperidina como antagonista de receptores de orexina
NI201300106A (es) Composición farmacéutica antihipertensiva
AR075260A1 (es) Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
CO6351799A2 (es) Derivados de estratrieno que comprenden bioisosteros heterociclicos para el anillo fenolico a

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181127